Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $81.7 million.

  • Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) rose 27.82% to $81.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.7 million, marking a year-over-year increase of 27.82%. This contributed to the annual value of $79.2 million for FY2024, which is 50.63% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) stood at $81.7 million, which was up 0.09% from $81.6 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) ranged from a high of $81.7 million in Q3 2025 and a low of $7.2 million during Q1 2021.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Shares Outstanding (Weighted Average) value was $63.8 million (recorded in 2024), while the average stood at $63.3 million.
  • Data for Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) shows a peak YoY soared of 455.43% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) stood at $21.7 million in 2021, then surged by 85.28% to $40.2 million in 2022, then spiked by 30.65% to $52.6 million in 2023, then skyrocketed by 50.63% to $79.2 million in 2024, then increased by 27.82% to $81.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $81.7 million in Q3 2025, compared to $81.6 million in Q2 2025 and $81.5 million in Q1 2025.